245 related articles for article (PubMed ID: 29192323)
41. Liposomal propranolol for treatment of infantile hemangioma at compounding pharmacies.
Nifli A; Liakopoulou A; Mourelatou E; Avgoustakis K; Hatziantoniou S
J Liposome Res; 2024 Feb; ():1-12. PubMed ID: 38335203
[TBL] [Abstract][Full Text] [Related]
42. Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.
Li P; Guo Z; Gao Y; Pan W
Oncol Rep; 2015 Jun; 33(6):3099-107. PubMed ID: 25872592
[TBL] [Abstract][Full Text] [Related]
43. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.
Greenberger S; Bischoff J
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a006460. PubMed ID: 22229118
[TBL] [Abstract][Full Text] [Related]
44. Oral propranolol: an effective, safe treatment for infantile hemangiomas.
Zaher H; Rasheed H; Hegazy RA; Hegazy RA; Abdelhalim DM; Gawdat HI
Eur J Dermatol; 2011; 21(4):558-63. PubMed ID: 21697036
[TBL] [Abstract][Full Text] [Related]
45. CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma.
Mai HM; Zheng JW; Wang YA; Yang XJ; Zhou Q; Qin ZP; Li KL
Chin Med J (Engl); 2013 Jan; 126(1):88-94. PubMed ID: 23286484
[TBL] [Abstract][Full Text] [Related]
46. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells.
Greenberger S; Boscolo E; Adini I; Mulliken JB; Bischoff J
N Engl J Med; 2010 Mar; 362(11):1005-13. PubMed ID: 20237346
[TBL] [Abstract][Full Text] [Related]
47. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.
Bertrand J; Sammour R; McCuaig C; Dubois J; Hatami A; Ondrejchak S; Boutin C; Bortoluzzi P; Laberge LC; Powell J
J Cutan Med Surg; 2012; 16(2):115-21. PubMed ID: 22513064
[TBL] [Abstract][Full Text] [Related]
48. Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution.
Mong EF; Akat KM; Canfield J; Lockhart J; VanWye J; Matar A; Tsibris JCM; Wu JK; Tuschl T; Totary-Jain H
Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1321-1332. PubMed ID: 29724816
[TBL] [Abstract][Full Text] [Related]
49. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial.
Zaher H; Rasheed H; Esmat S; Hegazy RA; Gawdat HI; Hegazy RA; El-Komy M; Abdelhalim DM
Eur J Dermatol; 2013; 23(5):646-52. PubMed ID: 24135427
[TBL] [Abstract][Full Text] [Related]
50. The role of propranolol in the treatment of infantile hemangioma.
Laranjo S; Costa G; Paramés F; Freitas I; Martins JD; Trigo C; Pinto FF
Rev Port Cardiol; 2014 May; 33(5):289-95. PubMed ID: 24906291
[TBL] [Abstract][Full Text] [Related]
51. No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age.
Li L; Wei L; Xu ZG; Ma L
Am J Clin Dermatol; 2019 Apr; 20(2):289-293. PubMed ID: 30618026
[TBL] [Abstract][Full Text] [Related]
52. Constitutive Store-Operated Ca(2+) Entry Leads to Enhanced Nitric Oxide Production and Proliferation in Infantile Hemangioma-Derived Endothelial Colony-Forming Cells.
Zuccolo E; Bottino C; Diofano F; Poletto V; Codazzi AC; Mannarino S; Campanelli R; Fois G; Marseglia GL; Guerra G; Montagna D; Laforenza U; Rosti V; Massa M; Moccia F
Stem Cells Dev; 2016 Feb; 25(4):301-19. PubMed ID: 26654173
[TBL] [Abstract][Full Text] [Related]
53. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.
Jinnin M; Medici D; Park L; Limaye N; Liu Y; Boscolo E; Bischoff J; Vikkula M; Boye E; Olsen BR
Nat Med; 2008 Nov; 14(11):1236-46. PubMed ID: 18931684
[TBL] [Abstract][Full Text] [Related]
54. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
Makkeyah SM; Elseedawy ME; Abdel-Kader HM; Mokhtar GM; Ragab IA
Pediatr Hematol Oncol; 2022 Apr; 39(3):215-224. PubMed ID: 34477031
[TBL] [Abstract][Full Text] [Related]
55. Osmundacetone Inhibits Angiogenesis of Infantile Hemangiomas through Inducing Caspases and Reducing VEGFR2/MMP9.
Ke C; Chen C; Yang M; Chen H; Li L; Ke Y
Anticancer Agents Med Chem; 2024; 24(2):125-131. PubMed ID: 37957872
[TBL] [Abstract][Full Text] [Related]
56. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.
Benny O; Duvshani-Eshet M; Cargioli T; Bello L; Bikfalvi A; Carroll RS; Machluf M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):768-76. PubMed ID: 15701867
[TBL] [Abstract][Full Text] [Related]
57. Is Infantile Hemangioma a Neuroendocrine Tumor?
Kaulanjan-Checkmodine P; Oucherif S; Prey S; Gontier E; Lacomme S; Loot M; Miljkovic-Licina M; Cario M; Léauté-Labrèze C; Taieb A; Moisan F; Rezvani HR
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563552
[TBL] [Abstract][Full Text] [Related]
58. Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
Przewratil P; Kobos J; Wnęk A; Szemraj J; Wyrzykowski D; Chrzanowska B; Andrzejewska E; Taran K
Immunol Lett; 2016 Jul; 175():44-9. PubMed ID: 27178307
[TBL] [Abstract][Full Text] [Related]
59. Urea-modulated UT-B urea transporter internalization is clathrin- and caveolae-dependent in infantile hemangioma-derived vascular endothelial cells.
Xiao L; Liu D; Zuo S; Zhu X; Wang Y; Dong C
J Cell Biochem; 2019 Apr; 120(4):5128-5136. PubMed ID: 30367514
[TBL] [Abstract][Full Text] [Related]
60. Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature.
Raphael MF; Breur JM; Vlasveld FA; Elbert NJ; Liem YT; Kon M; Breugem CC; Pasmans SG
Expert Opin Drug Saf; 2016; 15(2):199-214. PubMed ID: 26646657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
